LISTED medicinal cannabis company AusCann has announced the appointment of global pharmaceutical business executive, Ido Kanyon, as Chief Executive Officer commencing 22 May 2019.
Kanyon has held several Quality Assurance and Regulatory Affairs leadership roles at Teva, and was responsible for the company's specialty Medicine multi-billion specialty pipeline portfolio, with the stated goal of maximizing the value of the company's R&D investment on innovative medicines.
AusCann Chairman Dr Mal Washer commented: "Our extensive executive search generated an impressive field of candidates and Ido stood out for his leadership acumen and track record of commercial achievements throughout his career".
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Feb 19
